Impact of immunoprophylaxis with palivizumab on respiratory syncytial virus infection in preterm infants less than 35 weeks in Colombian hospitals

被引：0
|
作者：
Colmenares, Alejandro [1 ]
Galvis, Clara [1 ]
Cabrales, Lina [1 ]
Ibata, Linda [1 ]
Marulanda, Juliana [2 ]
Ovalle, Oscar [2 ]
Puello, Dionisio [3 ]
Rojas, Catherine [4 ]
Africano, Martha [5 ]
Ballesteros, Adriana [6 ]
Posso, Hector [7 ]
机构：
[1] Hosp Mil Cent, Bogota, Colombia
[2] Clin Materno Infantil, Bogota, Colombia
[3] Cin Crecer, Cartagena, Colombia
[4] Ctr Policlin Olaya, Bogota, Colombia
[5] Clin San Luis, Bucaramanga, Colombia
[6] Fdn Valle Lili, Cali, Colombia
[7] Hosp Mil Cent, Cali, Colombia
来源：
EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷
关键词：
D O I：
10.1183/13993003.congress-2023.PA2776
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Impact of the risk scoring model on the cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks in Canada
    Lanctot, K. L.
    Paes, B.
    Francis, P. L.
    Chiu, A.
    Hui, C.
    Oh, P., I
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A248 - A249
  • [42] Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants
    Staebler, Suzanne
    Blake, Stephanie
    [J]. POLICY POLITICS & NURSING PRACTICE, 2021, 22 (01) : 41 - 50
  • [43] Appropriateness of Age Thresholds for Respiratory Syncytial Virus Immunoprophylaxis in Moderate-Preterm Infants A Cohort Study
    Winterstein, Almut G.
    Knox, Caitlin A.
    Kubilis, Paul
    Hampp, Christian
    [J]. JAMA PEDIATRICS, 2013, 167 (12) : 1118 - 1124
  • [44] Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
    Null, D
    Bimle, C
    Weisman, L
    Johnson, K
    Steichen, J
    Singh, S
    Wang, E
    Asztalos, E
    Loeffler, AM
    Azimi, PH
    Lieberman, JM
    O'Donnell, NE
    Cooke, RJ
    McCormick, K
    Koo, W
    Hammami, M
    Milner, AD
    Gaon, P
    Nachman, S
    Tarpey, KP
    Sánchez, PJ
    Broyles, RS
    Bratcher, D
    Ball, MV
    Duda, FJ
    DeCuir, PM
    Pollara, B
    Nelson, LS
    Balbus, M
    Schultz, MJ
    Chipps, BE
    Givner, LB
    O'Shea, M
    Everard, M
    Pfeffer, K
    Page, AJ
    Dennehy, PH
    Modlin, J
    Rhodes, T
    DeVincenzo, N
    Nickerson, B
    Arrieta, A
    Boucher, FD
    Keeney, RE
    Young, TE
    Stevens, JC
    Ariagno, R
    Adams, M
    Polak, MJ
    Lynch, SK
    [J]. PEDIATRICS, 1998, 102 (03) : 531 - 537
  • [45] Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants: A note of caution
    Suresh, S
    Schilling, S
    Dakin, C
    Harris, MA
    [J]. JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2003, 39 (08) : 637 - 637
  • [46] Premature infants who get hospitalized for respiratory syncytial virus infection despite receiving palivizumab
    Afghani, B
    Ngo, T
    Zeitany, R
    Amin, A
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2006, 54 (01) : S133 - S133
  • [47] Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
    Caserta, Mary T.
    O'Leary, Sean T. R.
    Munoz, Flor M. M.
    Ralston, Shawn L.
    [J]. PEDIATRICS, 2023, 152 (01)
  • [48] Intensive Care Unit Admission Rates for Respiratory Syncytial Virus Infection as a Function of Age in Preterm Infants Born at 32-35-week Gestation and Not Receiving Immunoprophylaxis
    Simoes, Eric A. F.
    Ambrose, Christopher S.
    Wu, Xionghua
    Anderson, Evan J.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (03) : 331 - 331
  • [49] Hospital admission of high risk infants for respiratory syncytial virus infection:: implications for palivizumab prophylaxis
    Heikkinen, T
    Valkonen, H
    Lehtonen, L
    Vainionpää, R
    Ruuskanen, O
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 2005, 90 (01): : F64 - F68
  • [50] Clinical and Pharmacological Aspects of Immunoprophylaxis for Respiratory Syncytial Virus Infection in High-Risk Infants
    Lanari, Marcello
    Silvestri, Michela
    Rossi, Giovanni A.
    [J]. CURRENT DRUG METABOLISM, 2013, 14 (02) : 216 - 225
12345